These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

102 related items for PubMed ID: 21473798

  • 1. Chronic dietary supplementation with turmeric protects against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-mediated neurotoxicity in vivo: implications for Parkinson's disease.
    Mythri RB, Veena J, Harish G, Shankaranarayana Rao BS, Srinivas Bharath MM.
    Br J Nutr; 2011 Jul; 106(1):63-72. PubMed ID: 21473798
    [Abstract] [Full Text] [Related]

  • 2. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
    Novikova L, Garris BL, Garris DR, Lau YS.
    Neuroscience; 2006 Jun 19; 140(1):67-76. PubMed ID: 16533572
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one), a radical scavenger, prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in the substantia nigra but not the striatum.
    Kawasaki T, Ishihara K, Ago Y, Baba A, Matsuda T.
    J Pharmacol Exp Ther; 2007 Jul 19; 322(1):274-81. PubMed ID: 17429058
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. A neuroprotective agent, T-817MA (1-{3-[2-(1-benzothiophen-5-yl)ethoxy]propyl} azetidin-3-ol maleate), prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in mice.
    Kawasaki T, Ago Y, Kitao T, Nashida T, Takagi A, Takuma K, Matsuda T.
    Neuropharmacology; 2008 Oct 19; 55(5):654-60. PubMed ID: 18573265
    [Abstract] [Full Text] [Related]

  • 7. CEP-1347/KT-7515, an inhibitor of c-jun N-terminal kinase activation, attenuates the 1-methyl-4-phenyl tetrahydropyridine-mediated loss of nigrostriatal dopaminergic neurons In vivo.
    Saporito MS, Brown EM, Miller MS, Carswell S.
    J Pharmacol Exp Ther; 1999 Feb 19; 288(2):421-7. PubMed ID: 9918541
    [Abstract] [Full Text] [Related]

  • 8. Baicalein protects the brain against neuron impairments induced by MPTP in C57BL/6 mice.
    Mu X, He GR, Yuan X, Li XX, Du GH.
    Pharmacol Biochem Behav; 2011 Apr 19; 98(2):286-91. PubMed ID: 21262257
    [Abstract] [Full Text] [Related]

  • 9. Overexpression of Parkinson's disease-associated alpha-synucleinA53T by recombinant adeno-associated virus in mice does not increase the vulnerability of dopaminergic neurons to MPTP.
    Dong Z, Ferger B, Feldon J, Büeler H.
    J Neurobiol; 2002 Oct 19; 53(1):1-10. PubMed ID: 12360578
    [Abstract] [Full Text] [Related]

  • 10. Protective effects of Chunghyuldan against ROS-mediated neuronal cell death in models of Parkinson's disease.
    Kim HG, Ju MS, Kim DH, Hong J, Cho SH, Cho KH, Park W, Lee EH, Kim SY, Oh MS.
    Basic Clin Pharmacol Toxicol; 2010 Dec 19; 107(6):958-64. PubMed ID: 20629656
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Paroxetine prevents loss of nigrostriatal dopaminergic neurons by inhibiting brain inflammation and oxidative stress in an experimental model of Parkinson's disease.
    Chung YC, Kim SR, Jin BK.
    J Immunol; 2010 Jul 15; 185(2):1230-7. PubMed ID: 20566832
    [Abstract] [Full Text] [Related]

  • 13. Hexokinase II gene transfer protects against neurodegeneration in the rotenone and MPTP mouse models of Parkinson's disease.
    Corona JC, Gimenez-Cassina A, Lim F, Díaz-Nido J.
    J Neurosci Res; 2010 Jul 15; 88(9):1943-50. PubMed ID: 20143419
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Lipid-lowering drugs in the MPTP mouse model of Parkinson's disease: fenofibrate has a neuroprotective effect, whereas bezafibrate and HMG-CoA reductase inhibitors do not.
    Kreisler A, Gelé P, Wiart JF, Lhermitte M, Destée A, Bordet R.
    Brain Res; 2007 Mar 02; 1135(1):77-84. PubMed ID: 17196944
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Protective effects of synthetic kynurenines on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in mice.
    Acuña-Castroviejo D, Tapias V, López LC, Doerrier C, Camacho E, Carrión MD, Mora F, Espinosa A, Escames G.
    Brain Res Bull; 2011 May 30; 85(3-4):133-40. PubMed ID: 21419832
    [Abstract] [Full Text] [Related]

  • 19. Attenuation of MPTP-induced neurotoxicity and locomotor dysfunction in Nucling-deficient mice via suppression of the apoptosome pathway.
    Teng X, Sakai T, Liu L, Sakai R, Kaji R, Fukui K.
    J Neurochem; 2006 May 30; 97(4):1126-35. PubMed ID: 16686692
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.